New drug cocktail shows promise for Hard-to-Treat leukemia
NCT ID NCT01861314
First seen Oct 31, 2025 · Last updated Jun 12, 2026 · Updated 32 times
Summary
This early-phase study tested a combination of three drugs—bortezomib, sorafenib, and decitabine—in 15 adults with acute myeloid leukemia (AML), including older patients or those whose cancer returned. The main goal was to find the safest dose and check for side effects. Researchers also looked at whether a specific biomarker (miR-29b) could predict response. This is not a cure; the treatment aims to control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
Conditions
Explore the condition pages connected to this study.